P. Harpel

发表

The Hemodynamic and Fibrinolytic Response to Low Dose Epinephrine and Phenylephrine Infusions During Total Hip Replacement Under Epidural Anesthesia

N. Sharrock, R. Mineo, G. Go, 1992, Thrombosis and Haemostasis.

The John Charnley Award. Thrombogenesis during total hip arthroplasty.

C. Ranawat, E. Salvati, T. Sculco, 1995, Clinical orthopaedics and related research.

Dose response of intravenous heparin on markers of thrombosis during primary total hip replacement.

E. Salvati, T. Sculco, G. Westrich, 1999, Anesthesiology.

Comparison of extradural and general anaesthesia on the fibrinolytic response to total knee arthroplasty.

P. Williams-Russo, S. Haas, N. Sharrock, 1997, British journal of anaesthesia.

Changes in circulatory indices of thrombosis and fibrinolysis during total knee arthroplasty performed under tourniquet.

C. Ranawat, T. Sculco, M. Maynard, 1995, The Journal of arthroplasty.

The effect of epsilon aminocaproic acid and tranexamic acid on thrombus size and strength in a simulated arterial aneurysm.

R. Patterson, P. Harpel, 1971, Journal of neurosurgery.

Binding and activation of plasminogen on immobilized immunoglobulin G. Identification of the plasmin-derived Fab as the plasminogen-binding fragment.

P. Harpel, R. Sullivan, T. S. Chang, 1989, The Journal of biological chemistry.

Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein.

R. Silverstein, R. Nachman, L. Leung, 1985, The Journal of clinical investigation.

Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay.

P. Harpel, 1981, The Journal of clinical investigation.

Inhibitors of the Fibrinolytic Enzyme System

P. Harpel, N. Aoki, 1984, Seminars in thrombosis and hemostasis.

Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects.

J. Parrillo, A. Suffredini, P. Harpel, 1989, The New England journal of medicine.

Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration

D. Rifkin, S. Kojima, P. Harpel, 1991, The Journal of cell biology.

Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism.

V. Chang, P. Harpel, W. Borth, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon.

E. Rusinova, J. Rand, Xiao-Xuan Wu, 1998, Blood.

Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes.

R. Levin, P. Harpel, J. Harpel, 1989, Blood.

Inhibition of Tissue Plasminogen Activator Activity by Aspirin In Vivo and Its Relationship to Levels of Tissue Plasminogen Activator Antigen, Plasminogen Activator Inhibitor, and Their Complexes

R. Levin, P. Harpel, J. Harpel, 1989 .

Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin.

B. Gordon, T. Parker, P. Harpel, 1989, Proceedings of the National Academy of Sciences of the United States of America.

C[unk] inactivator inhibition by plasmin

P. Harpel, 1970 .

alpha2-Macroglobulin on human vascular endothelium

C. G. Becker, P. Harpel, 1976, The Journal of experimental medicine.

Oxidation of apolipoprotein(a) inhibits kringle‐associated lysine binding: The loss of intrinsic protein fluorescence suggests a role for tryptophan residues in the lysine binding site

W. Laws, P. Harpel, A. Hermann, 1997, Protein science : a publication of the Protein Society.

Novel Immunoenzyme Assays for Thrombin‐Antithrombin III and Thrombin‐α2‐Macroglobulin Complexes in Plasma

P. Harpel, JOHN W. FENTON Ii, 1986, Annals of the New York Academy of Sciences.

Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

R. Nachman, P. Harpel, B. S. Knudsen, 1987, The Journal of clinical investigation.

Binding of tissue plasminogen activator to cultured human endothelial cells.

K. Hajjar, R. Nachman, P. Harpel, 1987, The Journal of clinical investigation.

STUDIES ON HUMAN PLASMA α2-MACROGLOBULIN-ENZYME INTERACTIONS

P. Harpel, 1973, The Journal of experimental medicine.

Fibrin, Lipoprotein(a), Plasmin Interactions: A Model Linking Thrombosis and Atherogenesis a

P. Harpel, W. Borth, 1992, Annals of the New York Academy of Sciences.

Lipoprotein(a), Homocysteine, and Atherogenesis

P. Harpel, W. Borth, 1997 .

Lipoprotein(a): searching for a function.

P. Harpel, M. Taubman, M. Poon, 1996, Transactions of the American Clinical and Climatological Association.

Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

D. Rifkin, R. Levin, P. Harpel, 1984, The Journal of clinical investigation.

Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass.

R. Colman, L. Edmunds, P. Harpel, 1989, Blood.

Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.

K. Hajjar, D. Hajjar, R. Nachman, 1991, The Journal of biological chemistry.

Lipoprotein(a), Plasmin Modulation, and Atherogenesis

P. Harpel, A. Hermann, W. Borth, 1995, Thrombosis and Haemostasis.

Alpha-1-antitrypsin-human leukocyte elastase complexes in blood: quantification by an enzyme-linked differential antibody immunosorbent assay and comparison with alpha-2-plasmin inhibitor-plasmin complexes.

P. Harpel, M. Brower, M. S. Brower, 1983, Blood.

Plasmin inhibitor interactions. The effectiveness of alpha2-plasmin inhibitor in the presence of alpha2-macroglobulin

P. Harpel, 1977, The Journal of experimental medicine.

Histological localization of plasminogen activator and proteolytic activity in the human stomach and duodenum

S. Winawer, P. Harpel, P. Eras, 1970, Gut.

Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-alpha 2-plasmin-inhibitor complexes during cardiopulmonary bypass.

R. Colman, L. Edmunds, P. Harpel, 1989, Blood.

Fibrin-bound lipoprotein(a) promotes plasminogen binding but inhibits fibrin degradation by plasmin.

P. Harpel, V. Gurewich, J. Liu, 1994, Biochemistry.

Lipoprotein(a): a kinetic study of its influence on fibrin-dependent plasminogen activation by prourokinase or tissue plasminogen activator.

P. Harpel, V. Gurewich, J. Liu, 1993, Biochemistry.

Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes [see comments]

H. Fillit, J. Rand, P. Harpel, 1994 .

Binding of plasminogen to extracellular matrix.

R. Silverstein, R. Nachman, L. Leung, 1986, The Journal of biological chemistry.

Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator.

R. Silverstein, R. Nachman, L. Leung, 1984, The Journal of clinical investigation.

Location of the Major -(-Glutamyl)lysyl Cross-linking Site in Transglutaminase-modified Human Plasminogen (*)

E. Bendixen, L. Sottrup-jensen, P. Harpel, 1995, The Journal of Biological Chemistry.

Transglutaminases catalyze cross-linking of plasminogen to fibronectin and human endothelial cells.

E. Bendixen, P. Harpel, W. Borth, 1993, The Journal of biological chemistry.

Lipoprotein (a) is a substrate for factor XIIIa and tissue transglutaminase.

V. Chang, P. Harpel, W. Borth, 1991, The Journal of biological chemistry.

Degradation of Human Fibrinogen by Plasma α2-Macroglobulin-Enzyme Complexes

M. Mosesson, P. Harpel, 1973 .

Homocysteine, atherogenesis and thrombosis

P. Harpel, 1997 .

Homocysteine and hemostasis: pathogenic mechanisms predisposing to thrombosis.

P. Harpel, W. Borth, Xiaoxia Zhang, 1996, The Journal of nutrition.

Complex formation of platelet thrombospondin with histidine-rich glycoprotein.

R. Nachman, L. Leung, P. Harpel, 1984, The Journal of clinical investigation.

Identification of mechanisms that may modulate the role of lipoprotein(a) in thrombosis and atherogenesis.

P. Harpel, W. Borth, 1992, Annals of epidemiology.

Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin.

R. Silverstein, R. Nachman, P. Harpel, 1986, The Journal of biological chemistry.

α2–Plasmin Inhibitor - Plasmin Complexes in Normal and Hypertensive Pregnancy

K. Aleš, M. Druzin, P. Harpel, 1986 .

Assessment of Hageman factor activation in human plasma: quantification of activated Hageman factor-C1 inactivator complexes by an enzyme-linked differential antibody immunosorbent assay.

A. Kaplan, P. Harpel, B. Gruber, 1985, Blood.

Studies of C1 inactivator-plasma kallikrein complexes in purified systems and in plasma.

A. Kaplan, P. Harpel, M. Lewin, 1983, The Journal of biological chemistry.

Demonstration of covalent binding of lipoprotein(a) [Lp(a)] to fibrin and endothelial cells.

P. Harpel, V. Gurewich, J. Liu, 1998, Biochemistry.

Location of the major epsilon-(gamma-glutamyl)lysyl cross-linking site in transglutaminase-modified human plasminogen.

E. Bendixen, L. Sottrup-jensen, P. Harpel, 1995, The Journal of biological chemistry.

Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation.

R. Silverstein, L. Leung, P. Harpel, 1985, The Journal of biological chemistry.

Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.

P. Harpel, T. S. Chang, E. Verderber, 1985, The Journal of biological chemistry.

Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase.

P. Harpel, M. Brower, M. S. Brower, 1982, The Journal of biological chemistry.

Platelet alpha2-macroglobulin and alpha1-antitrypsin.

R. Nachman, P. Harpel, 1976, The Journal of biological chemistry.

Platelet histidine-rich glycoprotein.

R. Nachman, L. Leung, P. Harpel, 1989, Methods in enzymology.

Histidine-rich glycoprotein inhibits the antiproliferative effect of heparin on smooth muscle cells

D. Hajjar, R. Nachman, P. Harpel, 1987, The Journal of experimental medicine.

PLASMIN INHIBITOR INTERACTIONS The Effectiveness of a2-Plasmin Inhibitor in the Presence of a2-Macroglobulin*

P. Harpel, 2003 .

Plasmin-a2-Plasmin-Inhibitor Complexes During Cardiopulmonary Bypass

R. Colman, P. Harpel, Y. Wachtfogel, 2011 .

STUDIES ON HUMAN PLASMA α2-MACROGLOBULIN-ENZYME INTERACTIONS

P. Harpel, 1973, Journal of Experimental Medicine.

Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.

P. Harpel, 1971, The Journal of clinical investigation.

Binding of plasminogen to cultured human endothelial cells.

E. Jaffe, K. Hajjar, R. Nachman, 1986, The Journal of biological chemistry.

Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin.

N. Cooper, P. Harpel, 1975, The Journal of clinical investigation.

[65]C1 inactivator

P. Harpel, 1976 .

Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor.

D. Rifkin, P. Dennis, O. Saksela, 1989, The Journal of biological chemistry.

Protease inhibitors--a precarious balance.

P. Harpel, 1983, New England Journal of Medicine.

α2‐MACROGLOBULIN: AN INTRODUCTION

P. Harpel, M. Brower, M. S. Brower, 1983 .

Heat-induced fragmentation of human alpha 2-macroglobulin.

P. Harpel, T. Hugli, M. Hayes, 1979, The Journal of biological chemistry.

Thrombospondin forms complexes with single-chain and two-chain forms of urokinase.

R. Silverstein, R. Nachman, P. Harpel, 1990, The Journal of biological chemistry.

Alpha 2-macroglobulin and antithrombin-heparin cofactor: modulators of hemostatic and inflammatory reactions. Alpha 2-macroglobulin.

R. Rosenberg, P. Harpel, 1976, Progress in hemostasis and thrombosis.

A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever.

A. Schmaier, R. Colman, W. Blackwelder, 1988, The New England journal of medicine.

C1 inactivator inhibition by plasmin.

P. Harpel, 1970, The Journal of clinical investigation.

Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes.

A. Kaplan, P. Harpel, M. Lewin, 1985, The Journal of biological chemistry.

Studies on the interaction between collagen and a plasma kallikrein-like activity. Evidence for a surface-active enzyme system.

P. Harpel, 1972, The Journal of clinical investigation.

AN INHIBITOR OF PLASMA KALLIKREIN

P. Harpel, 1970 .

Chemokine receptor-8: potential role in atherogenesis.

P. Harpel, N. Haque, 2002, The Israel Medical Association journal : IMAJ.

CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells.

M. Koschinsky, J. Fallon, B. Gabel, 2000, Circulation.

Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells.

P. Harpel, M. Taubman, K. Dunsky, 1997, Circulation.

Histidine-rich glycoprotein is present in human platelets and is released following thrombin stimulation.

R. Nachman, L. Leung, P. Harpel, 1983, Blood.

α2–plasmin Inhibitor And α2-Macroglobulin-Plasmin Complexes In Plasma. Quantitation By An Enzyme-Linked Immunosorbent Assay

P. Harpel, 1981, Thrombosis and Haemostasis.

Apolipoprotein(a) is a human vascular endothelial cell agonist: studies on the induction in endothelial cells of monocyte chemotactic factor activity

P. Harpel, M. Taubman, M. Poon, 1997, Clinical genetics.

The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium.

J. Fallon, P. Harpel, M. Taubman, 2001, Blood.

Homocysteine and hemostasis : Pathogenetic mechanisms predisposing to thrombosis : Homocyst(e)ine, vitamins and arterial occlusive diseases

P. Harpel, W. Borth, Xiaoxia Zhang, 1996 .

Thrombogenesis during total hip arthroplasty

Nigel E. Sharrock, Thomas P. Sculco, Eduardo A. Salvati, 1995 .

Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion.

J. Fallon, P. Harpel, M. Taubman, 2004, Blood.

Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation.

G. Dangas, J. Fallon, R. Mehran, 1998, Journal of the American College of Cardiology.

Immunoimmobilization of α2-macroglobulin-β-trypsin complexes: A novel approach for the biochemical characterization of modulator-protease interactions☆

P. Harpel, M. Hayes, 1980 .

The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.

J. Fallon, D. Strickland, K. Kozarsky, 1997, The Journal of clinical investigation.

medium vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded The chemokine receptor CCR8 mediates human endothelial cell

J. Fallon, P. Harpel, M. Taubman, 2010 .

following thrombin stimulation Histidine-rich glycoprotein is present in human platelets and is released

R. Nachman, P. Harpel, L. Leung, 2011 .

Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes.

M. Mosesson, P. Harpel, 1973, The Journal of clinical investigation.

HYPOFIBRINOGENEMIC HEMORRHAGE

P. Harpel, N. Bang, F. Streuli, 1964 .

cell chemotaxis and metalloproteinase-2 secretion 8 (CCR8) mediates human vascular smooth muscle - Chemokine receptor

J. Fallon, P. Harpel, M. Taubman, 2013 .

Studies on human plasma C1 inactivator-enzyme interactions. II. Structural features of an abnormal C1 inactivator from a kindred with hereditary angioneurotic edema.

N. Cooper, P. Harpel, T. Hugli, 1975, The Journal of clinical investigation.

Circulating inhibitors of human plasma kallikrein

P. Harpel, 1975 .

Alpha 2-plasmin inhibitor-plasmin complexes in synovial fluid.

R. Inman, P. Harpel, 1986, Journal of Rheumatology.

Relative Affinity of Plasmin for the α1-Macroglobulin, Cl Inactivator and α1-Antitrypsin Inhibitors

P. Harpel, 1975, Thrombosis and Haemostasis.

Mouse uterine fluid plasminogen activator, acid phosphatase, and contraceptive hormones.

P. Harpel, F. Homburger, A. Treger, 1968, The American journal of physiology.

Plasminogen Activator in Mouse Uterine Fluid

P. Harpel, N. Bang, F. Homburger, 1966, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Immunoimmobilization of alpha 2-macroglobulin--beta-trypsin complexes: a novel approach for the biochemical characterization of modulator--protease interactions.

P. Harpel, M. Hayes, 1980, Analytical biochemistry.

C1 inactivator-C1s complexes in inflammatory joint disease.

R. Inman, P. Harpel, 1983, Clinical and experimental immunology.

The differentiation of esterase and fibrinolytic activity in human plasma euglobulin preparations.

P. Harpel, 1968, Thrombosis et diathesis haemorrhagica.

FORMATION OF Cl -Cl INHIBITOR AND KALLIKREIN-Cl INHIBITOR COMPLEXES DURING CARDIOPULMONARY BYPASS

R. Colman, P. Harpel, Y. Wachtfogel, 1987, Thrombosis and Haemostasis.